Pharma Stocks
-
Takeda (TSE:4502) Valuation in Focus After Lowered FY2026 Guidance and VYVANSE Generic Impact
Takeda Pharmaceutical (TSE:4502) updated its outlook for the fiscal year ending March 2026, lowering guidance after reporting declines in both…
Read More » -
Pharma sector struggles, top firms hold ground
3 companies reported profit growth, 6 saw declines in FY25 02 November, 2025, 10:10 pm Last modified: 03 November, 2025,…
Read More » -
Strong Q3 Results Drive 11% Revenue Growth
TLDR Vertex’s Q3 2025 revenue jumps 11% driven by CF therapies and new drugs. Vertex’s cystic fibrosis treatments boost Q3…
Read More » -
Did Stevanato Group’s (STVN) German Manufacturing Expansion Just Shift Its Advanced Drug Delivery Investment Narrative?
Stevanato Group S.p.A. recently announced a significant expansion of its drug delivery system manufacturing capacity by adding over 2,500 square…
Read More » -
Strides Pharma shares rally 10% to hit all-time high; DAM Capital sees room for re-rating
Shares of Strides Pharma Ltd. surged 10% to a record high of ₹1,025 on Monday, November 3, extending gains for…
Read More » -
A Look at Amneal Pharmaceuticals (AMRX) Valuation After Robust Earnings and New FDA Respiratory Approval
Amneal Pharmaceuticals (AMRX) drew attention following a packed week of news. The company delivered higher sales and improved profitability last…
Read More » -
Royalty Pharma’s Major Royalty Deals and $2B Raise Could Be a Game Changer for RPRX
In the past week, Royalty Pharma announced it raised US$2.0 billion through senior unsecured notes and acquired royalties related to…
Read More » -
Phibro Animal Health Shares Surge 103% in 2025 Amid New Market Expansions
Ever wonder if Phibro Animal Health is actually a bargain right now? You are not alone. Many investors are examining…
Read More » -
Are these 3 pharma companies the market’s best-kept secret? Their numbers say yes. – Stock Insights News
The Indian pharmaceutical industry has always played a pivotal role in the global healthcare industry. While India has always been…
Read More » -
Evaluating BridgeBio Pharma After 122% Rally and Clinical Trial Breakthroughs
Wondering if BridgeBio Pharma is now a bargain or still too risky? You’re not alone. Let’s dig into what the…
Read More »